secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001104659-26-026146
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Sagimet Biosciences Reports 2025 Financial Results and MASH/Acne Program Updates
--------------------------------------------------------------------------------

- Cash and marketable securities $113.1M; net loss $51M for full year 2025.
- Completed Phase 1 PK trial of denifanstat+resmetirom; Phase 2 combo trial in F4 MASH expected 2H 2026.
- Exclusive license from TAPI for innovative resmetirom API forms to develop fixed-dose combination.
- Ascletis reported positive Phase 3 acne data for denifanstat; NDA accepted by China NMPA.
- Initiated Phase 1 trial of TVB-3567, a FASN inhibitor for acne.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/0001104659-26-026146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/tm268496d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-026146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer